Royal Bank of Canada
EPRS

Royal Bank of Canada’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Royal Bank of Canada’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-68
Closed – – 6913
2016
Q2 		$0 Buy
+68
New +$109 ﹤0.01% 6864
2015
Q3 		– Sell
-11,850
Closed -$68K – 7101
2015
Q2 		$68K Buy
+11,850
New +$80.9K ﹤0.01% 5058
2015
Q1 		– Sell
-25,576
Closed -$145K – 6806
2014
Q4 		$145K Hold
25,576
– – ﹤0.01% 4547
2014
Q3 		$184K Buy
+25,576
New +$221K ﹤0.01% 4248

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Royal Bank of Canada's EPRS Position: Q3 2016 in Review

Royal Bank of Canada sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 68 shares.

Royal Bank of Canada first reported a position in EPRS in Q3 2014 and held it in 4 quarters. The position peaked at $184K in Q3 2014. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

  • Royal Bank of Canada reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
  • Royal Bank of Canada sold 68 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016.
  • Royal Bank of Canada first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2014 and held it in 4 quarters.
  • Royal Bank of Canada's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $184K in Q3 2014.
  • 3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Royal Bank of Canada's 13F filing for Q3 2016, filed 14 Nov 2016.